XOMA to Present New Strategic Initiatives at the Cowen and Company 37th Annual Health Care Conference
February 28 2017 - 7:00AM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of therapeutic antibodies, announced today that Jim
Neal, Chief Executive Officer, will present the company’s new
strategic initiatives and value drivers at the Cowen and Company
37th Annual Health Care Conference on Tuesday, March 7, 2017 at
11:20 a.m. ET. The conference is being held at the Boston Marriott
Copley Place hotel.
A live audio webcast of the presentation can be accessed in the
Investors and Media section of XOMA's website
at http://investors.xoma.com/events.cfm. An archived version
of the webcast will be available via replay for 90 days following
the presentation.
About XOMA CorporationXOMA discovers and
develops innovative antibody therapeutics. XOMA has an extensive
portfolio of products, programs, and technologies that are the
subject of licenses the company has in place with other biotech and
pharmaceutical companies. There are more than 20 such programs
that are fully funded by partners and could produce milestone
payments and royalty payments in the future. XOMA continues to
advance Phase 2 development activities for 358, an allosteric
monoclonal antibody that reduces insulin receptor activity, as the
antibody could have a major impact on the treatment of
hyperinsulinism, particularly congenital hyperinsulinism and
hypoglycemia after bariatric surgery. For more information,
visit www.xoma.com.
CONTACTS:
Investor contact:
Luke Heagle
Pure Communications
+1 910-726-1372
lheagle@purecommunications.com
Media contact:
Colin Sanford
Pure Communications
+1 415-946-1094
csanford@purecommunications.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024